• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chinese Medical Journal >Evaluation of ~(99m)Tc-MIBI myocardial perfusion imaging with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease
【24h】

Evaluation of ~(99m)Tc-MIBI myocardial perfusion imaging with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease

机译：静脉输注三磷酸腺苷对〜（99m）Tc-MIBI心肌灌注显像在冠心病诊断中的价值

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To evaluate the feasibility, safety and diagnostic accuracy of pharmacologic stress of ~(99m)Technetium-MIBI single-photon emission computed tomography (SPECT) with intravenous adenosine triphosphate (ATP) in patients with suspected coronary artery disease. Methods The study group included 263 patients who were suspected of having coronary artery disease. All patients underwent ~(99m)Tc-MIBI myocardial perfusion imaging with ATP infusion (0.16 mg/kg body weight per min for 5 min). 20 mCi of ~(99m)Tc-MIBI were injected 3 minutes after the start of ATP infusion. Myocardial SPECT images were obtained 60 minutes later. Then, two days later, 20 mCi of ~(99m)Tc-MIBI were administered at rest and myocardial SPECT was repeated. 51 patients also underwent coronary angiography within two weeks for evaluation of sensitivity and specificity of ATP-myocardial perfusion imaging in detection of coronary artery disease. The occurrence of cardiac and non-cardiac adverse effects was carefully monitored during and after intravenous ATP infusion. Results The ATP infusion protocol was completed in all patients. Although 59% of the patients had various kinds of adverse effects, most of them were mild. No patient required aminophyline. The most severe adverse effect was second degree type Ⅱ atria-ventricular block (4/263), but all events were transient. The sensitivity and specificity of ATP-myocardial perfusion imaging were 97% and 82%, respectively. Conclusions It is shown that ~(99m)Technetium-MIBI SPECT with intravenous ATP is a safe and feasible technique for detecting coronary artery disease in patients unable to perform the exercise test.
机译：目的探讨〜（99m）Tech-MIBI单光子发射计算机断层扫描（SPECT）和静脉内三磷酸腺苷（ATP）药物治疗可疑冠心病的可行性，安全性和诊断准确性。方法研究组包括263例怀疑患有冠心病的患者。所有患者均接受〜（99m）Tc-MIBI心肌灌注显像，并接受ATP灌注（每分钟0.16 mg / kg体重，持续5分钟）。在开始ATP输注3分钟后，注入20 mCi的〜（99m）Tc-MIBI。 60分钟后获得心肌SPECT图像。然后，两天后，在静息状态下服用20 mCi的〜（99m）Tc-MIBI，并重复心肌SPECT。 51名患者还在两周内接受了冠状动脉造影，以评估ATP心肌灌注成像在检测冠状动脉疾病中的敏感性和特异性。在静脉内ATP输注期间和之后，仔细监测心脏和非心脏不良反应的发生。结果所有患者均完成了ATP输注方案。尽管59％的患者有各种不良反应，但大多数都是轻度的。没有患者需要氨基茶碱。最严重的不良反应是Ⅱ度Ⅱ度心室传导阻滞（4/263），但所有事件都是短暂的。 ATP心肌灌注显像的敏感性和特异性分别为97％和82％。结论：〜（99m）net-MIBI SPECT静脉内ATP是检测运动试验不能进行的冠心病的一种安全，可行的技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号